Radiometabolite Analysis Services for Radiopharmaceutical Ex Vivo Studies
Rdcthera offers radiometabolite analysis services to help release the potential of radiopharmaceutical research. Metabolic pathways for radiopharmaceuticals are key to confirming efficacy and safety. We provide leading pharmaceutical companies, biotechnology firms, academics, researchers, and institutions with exhaustive knowledge of radiopharmaceutical metabolism to assist in the development process for next-generation therapeutics.
Introduction to Radiometabolite Analysis
Radiometabolite analysis is the study of metabolic pathways and various transformations of radiolabeled compounds within biological systems. Such, radiometabolite analysis in radiopharmaceutical studies is relevant for providing information about
- Metabolic Pathways - The tracing of radiopharmaceuticals in the body, on how it is being metabolized.
- Efficacy Optimization - Metabolic transformation knowledge in enhancing therapeutic effectiveness.
- Safety Assessment - Potential toxic metabolite detection for the improvement of safety profiles.
Fig.1. Ex vivo radiometabolite analysis of [ 18 F]9 in the brain and plasma of rats at 20 and 60 min post-injection. (Xiao Z, et al., 2022)
Key Applications
| Application |
Description |
| Drug Development |
With the help of accurate metabolic data, quickly speed up the development of radiopharmaceuticals. |
| Regulatory Compliance |
Provide robust metabolite data to support regulatory compliance. |
| Biomarker Discovery |
Identify potential biomarkers for disease diagnosis and monitoring. |
Our Radiometabolite Analysis Services
Rdcthera provides an end-to-end solution for radiometabolite analysis, designed to meet all the complex needs associated with radiopharmaceutical research. Equipped with advanced methodologies and technologies, it offers precise, reliable, and actionable insights into metabolic pathways of radiopharmaceuticals.
| Service Category |
Service |
Description |
| Metabolite Profiling |
High-Resolution Metabolite Identification |
Utilizing HRMS and NMR spectroscopy for precise identification and structural elucidation of radiometabolites. |
| Quantitative Metabolomics |
Accurate quantification of metabolite concentrations and fluxes to understand drug distribution, efficacy, and potential toxicities. |
| Dynamic Metabolic Pathway Elucidation |
Pathway Mapping and Reconstruction |
Advanced computational mapping of metabolic pathways, providing insights into biochemical transformations at cellular and systemic levels. |
| Kinetic Studies |
Analysis of formation and clearance rates of radiometabolites to optimize dosing regimens and understand drug metabolism dynamics. |
| Customized Analysis Solutions |
Targeted Metabolomics |
In-depth study of certain radiometabolites appropriate for the investigation helps to reveal critical metabolic transformations. |
| Global Metabolomics |
It provides an overview of all metabolites in samples, thus giving a wide perspective on the metabolic impact of radiopharmaceuticals. |
| Additional Support Services |
Data Interpretation and Reporting |
Expert in data interpretation and reporting for appropriate decision-making. |
| Consultative Support |
Scientific support from study design through data analysis and interpretation on every project. |
| Regulatory Documentation |
Assistance in regulatory documentation to comply with industrial standards and guidelines in radiopharmaceutical development. |
Our Technologies and Methodologies
- Stable Isotope Labeling
We use of isotope-labeled compounds for tracing metabolic pathways and enhancing metabolic flux analysis accuracy.
- Liquid Chromatography-Mass Spectrometry
Sensitive and specific detection of radiometabolites, ideal for complex biological matrices.
- Gas Chromatography-Mass Spectrometry
Comprehensive analysis of volatile and semi-volatile radiometabolites.
Ready to take your radiopharmaceutical research to the next level with our radiometabolite analysis services? Contact Rdcthera today to discuss your project and request a quote. Our team is here to support your journey toward innovative solutions in radiopharmaceutical development.
Reference
- Xiao Z, Wei H, Xu Y, et al. (2022). Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination. Acta Pharm Sin B. 12(4):1963-1975.
For research use only. Not intended for any clinical use.
Related Service
